DALLAS, Dec. 8 /PRNewswire-FirstCall/ -- Refocus Group, Inc. (www.refocus-group.com), a medical device company engaged in the research and development of treatments for eye disorders, announced today that it filed to terminate the registration of its common stock with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, on Dec. 7, 2005. Effective today, the company will no longer be subject to SEC reporting requirements and its common stock will no longer be quoted on the OTC Bulletin Board.
About Refocus Group
Refocus Group (www.refocus-group.com) is a Dallas- based medical device company engaged in the research and development of treatments for eye disorders. Refocus holds about 90 domestic and international pending applications and issued patents, the vast majority directed to methods, devices and systems for the treatment of presbyopia, ocular hypertension and primary open-angle glaucoma.
Refocus Group, Inc.
CONTACT: David Doolittle of Refocus Group, +1-404-879-9266, firstname.lastname@example.org